

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Stuart Alan Grossman	POSITION TITLE Professor of Oncology, Medicine and Neurosurgery		
eRA COMMONS USER NAME (credential, e.g., agency login) SKIP11			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
Harvard College, Cambridge, MA	BA	1969	Biology
University of Rochester, Rochester, NY	MD	1973	Medicine

A. Personal Statement

I am well suited to serve as participating faculty for Dr. Bhujwala's P50 ICMIC grant with regard to expertise in mentoring career development trainees, and in providing clinical trials, oncology and neuro-oncology perspectives. I have served as the Director of Neuro-Oncology at the Johns Hopkins Comprehensive Cancer Center (1981-present) and as Principal Investigator for the Johns Hopkins NIH funded T32 fellowship training grant "Research Training in Neuro-Oncology" (1987-present), the NIH-funded New Approaches to Brain Tumor Therapy (NABTT), CNS Consortium (1994-2008) and the NIH-funded Adult Brain Tumor Consortium (2009-present). In addition, I have served as principal investigator of many phase I, II, and III brain tumor trials and have supervised many junior faculty and fellow research projects. In addition, I can be of assistance in coordinating the resources and skills within the Johns Hopkins Brain Cancer program and NIH-funded the Adult Brain Tumor Consortium to conduct relevant research projects related to this P50 grant.

B. Positions and Honors

Positions and Employment

1973-76	Intern and Resident, Internal Medicine, Strong Memorial Hospital, Rochester, NY
1976-78	National Health Services Corps, US Public Health Service, Greenwood, WI
1978-79	Attending Physician, Department of Internal Medicine, Marshfield Clinic, Marshfield, WI
1979-81	Fellow, Oncology and Medicine, Johns Hopkins Univ School of Medicine, Baltimore, MD
1981-82	Instructor, Oncology and Medicine, Johns Hopkins Univ School of Medicine, Baltimore, MD
1982-89	Assistant Professor, Oncology, Medicine & Neurosurgery, Johns Hopkins University
1989-98	Associate Professor, Oncology, Medicine & Neurosurgery, Johns Hopkins University
1998-	Professor Oncology, Medicine & Neurosurgery, Johns Hopkins Univ School of Medicine

Other Experience and Professional Memberships

1981	Director, Neuro-Oncology, Johns Hopkins Oncology Center, Baltimore, MD
1987	Director, NIH funded T32 Neuro-Oncology Training Program, Johns Hopkins Cancer Center
1994-08	Principal Investigator and Director of Operations Office, the NABTT CNS Consortium
2005	Director, Brain Cancer Program, Johns Hopkins Comprehensive Cancer Center
2009	Principal Investigator and Director of Operations Office, Adult Brain Tumor Consortium
2010	Member, NCI Brain Malignancies Steering Committee (BMSC)

Honors

1973	M.D. with Distinction in Research & Alpha Omega Alpha, University of Rochester
1976	Lawrence E. Young Award, University of Rochester
1978	Plaque Award, U.S. Public Health Service
1980-81	National Cancer Institute, Research Fellowship Award
1980-81	Clinical Fellowship Award, American Cancer Society
1983-86	Jr. Faculty Clinical Fellowship, American Cancer Society
1985	Fellow, American College of Physicians
1994	Award for National Activities in Cancer Pain, National Coalition for Cancer Survivors

1999-01	President, Society for Neuro-Oncology
2000	Farber Award for Outstanding Contributions to Neuro-Oncology, AANS
2007	Director's Teaching Award in Clinical Science, Johns Hopkins Comprehensive Cancer Center

C. Selected Peer-reviewed Publications (from >150 peer-reviewed publications)

Most relevant to the current application

1. Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, Gilbert M, Newton HB, Hellman R. A Phase III study comparing three cycles of infusional BCNU/cisplatin followed by radiation therapy with radiation therapy and concurrent BCNU for patients with newly diagnosed supratentorial glioblastoma multiforme (ECOG 2394). *J Clin Oncol.* 2003; 21:1485-91.
2. Nabors BL, Mikkelsen T, Carson KA, Wittemer SM, Colevas D, Grossman SA. A phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. *J Clin Oncol*, 2007; 25:1651-1657.
3. Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy D, Tatter SB, Dolan ME. Phase I trial of GliadelTM plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma. *J Clin Oncol*, 2007; 25: 399-404.
4. Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic Factors for Survival in Adult Patients with Recurrent Glioma Enrolled on New Approaches to Brain Tumor Therapy "NABTT" CNS Consortium Phase I and II Clinical Trials. *J Clin Oncol.* 2007; 25:2601-6.
5. Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko KJ. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. *Neuro-Oncol* 2008;10:190-8. PMID2613821.
6. Grossman SA, Carson, KA, Phuphanich, S, Batchelor, T, Peereboom, D, Nabors LB, Lesser, G., Hausheer F, Supko, JG. Phase I and Pharmacokinetic Study of Karenitecin in Patients with Recurrent Malignant Gliomas. *Neuro Oncol.* 2008;10:608-16. PMID2666235.
7. Chen H, Shah AS, Girgis RE, Grossman SA. Transmission of glioblastoma multiforme after bilateral lung transplantation. *J Clin Oncol.* 2008; 26:3284-5. PMC Journal - In Process.
8. Lustig R, Grossman SA, Mikkelsen T, Lesser G, Ye X, Desideri S, Fisher J, Wright J Phase II study of Pre-radiation R115777 (Zarnestra) in adult patients with newly diagnosed glioblastoma multiforme. *Neuro Oncol.* 2008; 10:1004-9. PMID2718997.
9. Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. The association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. *J Clin Oncol.* 2009; 27:1082-6. PMID2667812
10. Blakeley JO, Olson J, Grossman SA, He X, Weingart J, and Supko JG. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. *J. Neurooncol.* 2009; 91:51-58. PMC Journal - In Process.
11. Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, Piantadosi S, Fine H. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: A multicenter phase II trial. *J Clin Oncol.* 2009; 27:4155-61. PMID2734427.
12. Grossman SA, Ye X, Piantadosi S, Nabors LB, Rosenfeld M, Fisher J. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States. *Clin Cancer Res* 2010. PMID2861898 [Available on 2011/4/15].
13. Phuphanich S, Supko JG, Carson KA, Grossman SA, Nabors LB, Mikkelsen T, Lesser G, Rosenfeld S, Desideri S, Olson J. Phase I clinical trial of bortezomib in adults with recurrent malignant gliomas, *J. Neuro-Onc*, 2010. PMC Journal - In Process.
14. Peereboom, DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelsen T, Fisher J, Desideri S, He X, Grossman SA. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas, *J Neurooncol*, in press, 2010. PMC Journal - In Process.
15. Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. *Neurooncol*, 2010 Oct;12(10):1071-7. Epub 2010 Jul 8. PMC Journal - In Process.

D. Research Support

Ongoing Research Support

2P50CA103175-06A2 (Bhujwalla)
NCI JHU-ICMIC PROGRAM

09/22/11-07/31/16

To accelerate Clinical Roles for molecular imaging in cancer models and cancer care.

UO1 CA137443 (Grossman/Prados)

01/01/09–12/31/13

NIH/NCI

Adult Brain Tumor Consortium

The goals of this project are to safely and efficiently introduce novel anticancer agents into the treatment of high grade primary brain tumors through the conduct of phase 1-2 clinical trials, 2) To proactively seek collaboration with other NCI-funded clinical trials mechanisms and researchers devoted to finding promising new treatment approaches for adult brain tumors, and 3) To incorporate pharmacokinetic and pharmacodynamic endpoints (to include imaging and translational laboratory studies) as appropriate into phase 1-2 studies to facilitate future development of new treatment approaches.

UO1 CA137443-01S1 (Grossman)

06/01/09-05/31/12

NIH/NCI

Adult Brain Tumor Consortium –ARRA Supplement 1

This Phase 1b study will be the first to combine cediranib (angiogenesis inhibitor) and cilengitide (tumor invasion inhibitor) in patients with recurring glioblastoma and provides an excellent opportunity to study mechanisms of tumor response and relapse using correlative studies

T32 CA009574 (Grossman)

07/01/87-06/30/13

NIH/NCI Inst. National Research Service Award

Research Training in Neuro-Oncology

The goals of this project are to train neurosurgeons, radiation therapists, medical and pediatric oncologists, and neurologists for academic careers in neuro-oncology.

U10CA16116 (Forastiere)

06/18/04-04/30/16

NIH/ECOG

The major goals of this project are to develop and implement clinical research protocols and correlative laboratory studies within ECOG

U01 CA140204-01A2 (Wahl)

09/19/11-08/31/12

NIH/NCI

Multi-Modality Quantitative Imaging for Evaluation of Response to Cancer Therapy

The goals of this project is to develop, optimize, and validate approaches

for combining multiple image-derived parameters obtained from quantitative imaging procedures in order to optimally predict and assess treatment response. We will apply and evaluate these methods in three clinical trials: dynamic and static FDG and FLT PET/CT to assess lung cancer response to cytotoxic chemotherapy; PET/CT and DCE- and DW-MRI in breast cancer response; and SPECT/CT, PET/CT and DCE- and DW-MRI to predict response of brain tumors to anti-angiogenic therapy combined with combined chemo- and immuno-therapy

Completed Projects Within Last Three Years

P30CA006973 (Nelson)

05/01/12–04/30/12

NIH/NCI

Regional Oncology Research Center

The goal is to foster cancer-focused research, in part through the creation of formal program comprising the activities of a group of investigators who share common scientific interests and goal and participate in competitively funded research. Dr. Grossman is a Program Director.

NCI 5P30CA006973-46 (Nelson)

05/07/97-04/30/11

Regional Oncology Research Center

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC) is dedicated to research and education in cancer and related disorders and to the prompt application of new knowledge to the treatment of patients and to the prevention of neoplastic diseases. This application requests continued CCSG support for SKCCC's research programs and shared resources. The SKCCC is a multi-disciplinary, interdepartmental center of the Johns Hopkins University. There is a broad base of ongoing cancer research at Johns Hopkins. The special scientific programs of the Cancer Center are interdisciplinary in character and are focused on human disease. A wide range of activity is encompassed ranging from fundamental research into the molecular genetics of human tumorigenesis to clinical trials of new antitumor treatments. The Cancer Center has established eleven major research programs: Cancer Biology (Baylin), Hematologic Malignancies and BMT (Ambinder, Jones), Cancer Immunology (Pardoll), Viral Oncology (Hayward), Cancer Prevention and Control (Groopman), Chemical Therapeutics (Isaacs, Cole), Prostate Cancer (Nelson and Carducci), Breast Cancer (Davidson, Sukumar), Gastrointestinal Cancer (Kern, Hidalgo), Upper Aerodigestive Cancer (Rudin, Sidransky), Brain Cancer (Grossman, Brem, Laterra). Twenty-two Shared Resources support the needs of Cancer Center investigators: Animal Resources, Bioinformatics, Microarray, Cancer Functional Imaging, Cell Imaging, Common Equipment, Cytogenetics, Experimental Irradiators, Flow Cytometry, Glassware Washing, Mass Spectrometry, Medicinal Chemistry, Specimen Accessioning Core (SAC), Tissue Array Core, Pharmacology Analytical Core, Human Immunology, Cell Processing and Gene Therapy, Cellular Therapy (GEL), Research Informatics, Biostatistics, Research Pharmacy, and the Clinical Research Office. Interdisciplinary research seminars and research training programs provide valuable opportunities for interdisciplinary interaction and collaboration. Cancer Center developmental funds are used to support faculty recruitment and innovative research; development of shared resources; and a small allocation to pilot projects.

NCI UO1-CA-62475 Consortium Headquarters (Grossman)03/21/94-12/31/08

New Approaches to Brain Tumor Therapy CNS Consortium

Overall grant for NABTT CNS Consortium and Operations Office. The primary long-term objective of this proposal is to improve the therapeutic outcome for adults with primary brain tumors accomplished by participating in Phase I and II clinical evaluations of promising new agents biologic approaches, and routes of administration in the treatment of primary malignancies of the central nervous system (CNS) through the CNS consortium titled "New Approaches to Brain Tumor Therapy (NABTT)." The secondary long-term objective of this proposal is to utilize this consortium to share human brain tumor specimens as well as other clinical and laboratory data to conduct additional research pertaining to (1) the basic biology of primary brain tumors, (2) the neuro-pharmacology of new therapies for primary brain tumors, and (3) improving the care and quality of life of adults with primary brain tumors.

NCI UO1-CA-62474 Institutional Site (Brem)

03/21/94-12/31/08

New Approaches to Brain Tumor Therapy CNS Consortium

Grant for Johns Hopkins to work as a member institution within the NABTT CNS Consortium

Major goal: The primary long-term objective of this proposal is to improve the therapeutic outcome for adults with primary brain tumors accomplished by participating in Phase I and II clinical evaluations of promising new agents biologic approaches, and routes of administration in the treatment of primary malignancies of the central nervous system (CNS) through the CNS consortium titled "New Approaches to Brain Tumor Therapy (NABTT)." The secondary long-term objective of this proposal is to utilize this consortium to share human brain tumor specimens as well as other clinical and laboratory data to conduct additional research pertaining to (1) the basic biology of primary brain tumors, (2) the neuro-pharmacology of new therapies for primary brain tumors, and (3) improving the care and quality of life of adults with primary brain tumors.